Replies to post #125135 on Biotech Values

[DewDiligence]

Effient’s advantage vs Plavix was greater in secondary PCI than in primary PCI, according to a post-hoc analysis of the TRITON-TIMI 38 study conducted by LLY:

http://finance.yahoo.com/news/New-Analysis-Data-Presented-prnews-1512705521.html?x=0&l=1

For this analysis, primary PCI was defined as PCI <=12 hours from patient presentation with ACS, while secondary PCI was any PCI done later.

LLY has been doing a lot of data mining to try to lift the disappointing sales of Effient (#msg-66185095, #msg-47849149), but so far it hasn’t helped.